Aspect Biosystems

Tamer Mohamed, Ph.D., Founder and CEO

Oct. 10 | 3:00pm | Rentschler ATMP Ballroom 

Vancouver, BC, Canada


Aspect Biosystems is a biotechnology company pioneering the development of bioprinted tissue therapeutics to transform how we treat currently incurable diseases. Aspect is creating these next generation cell therapies by applying its full-stack therapeutic platform, which combines the company’s proprietary bioprinting technology, therapeutic cells, biomaterials, and computational design. Aspect’s bioprinted tissue therapeutics are designed to replace, repair, or supplement biological function inside the body with the aim of treating diseases such as type 1 diabetes as well as genetic and acquired liver diseases. In April 2023, Aspect Biosystems entered a US$2.6B+ partnership with Novo Nordisk, one of the largest pre-clinical deals in the industry, to develop bioprinted tissue therapeutics for diabetes and obesity.

By using this website you agree to accept our Privacy Policy and Terms & Conditions